doi:10.3969/j.issn.1004-583X.2026.06.013

Abstract

CLC Number:

R587.29

Add to citation manager EndNote|Ris|BibTeX

URL: https://www.lchc.cn/EN/10.3969/j.issn.1004-583X.2026.06.013

https://www.lchc.cn/EN/Y2026/V41/I6/556

Figures/Tables 1

References 37

[1]	Armstrong DG, Kanda VA, Lavery LA, et al. Mind the gap: Disparity between research funding and costs of care for diabetic foot ulcers[J]. Diabetes Care, 2013, 36(7):1815-1817.doi: 10.2337/dc12-2285. pmid: 23801792
[2]	Xu Z, Ran X. Diabetic foot care in China: Challenges and strategy[J]. Lancet Diabetes Endocrinol, 2016, 4(4):297-298.doi: 10.1016/S2213-8587(16)00051-6.
[3]	Bakker K, Apelqvist J, Schaper NC, et al. Practical guidelines on the management and prevention of the diabetic foot 2011[J]. Diabetes Metab Res Rev, 2012,28 Suppl 1:225-231.doi: 10.1002/dmrr.2253.
[4]	Bergin SM, Alford JB, Allard BP, et al. A limb lost every 3 hours: can Australia reduce amputations in people with diabetes?[J]. Med J Aust, 2012, 197(4):197-198.doi: 10.5694/mja10.10837. pmid: 22900854
[5]	Hamilton EJ, Scheepers J, Ryan H, et al. Australian guideline on wound classification of diabetes-related foot ulcers: Part of the 2021 Australian evidence-based guidelines for diabetes-related foot disease[J]. J Foot Ankle Res, 2021, 14(1):60.doi: 10.1186/s13047-021-00503-6. pmid: 34861898
[6]	Perrin BM, Hamilton EJ, Chuter V, et al. Australian foot health and disease in diabetes strategy 2030:Improving the foot health of people living with diabetes[EB/OL]. https://diabetesfeetaustralia.org/,(2024)[2026-05-21].
[7]	Scheen AJ. Lower limb amputations:Protection with GLP-1 receptor agonists rather than increased risk with SGLT2 inhibitors?[J]. Diabetes Metab, 2022, 48(2):101325.doi: 10.1016/j.diabet.2022.101325.
[8]	Zhang Y, Liu H, Yang Y, et al. Incidence and risk factors for amputation in Chinese patients with diabetic foot ulcers: A systematic review and meta-analysis[J]. Front Endocrinol (Lausanne), 2024, 15:1405301. doi: 10.3389/fendo.2024.1405301.
[9]	Li G, Lu Q, Wen B, et al. Analysis of the incidence and influencing factors of high-risk foot in elderly patients with type 2 diabetes in a community in Beijing[J]. PLoS One, 2025, 20(3):e0313794.doi: 10.1371/journal.pone.0313794.
[10]	Yao JL, Li JX, Ming XC, et al. Epidemiological characteristics of adult inpatients with diabetes-related chronic non-healing wounds in Hainan province[J]. Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi, 2026, 42(3):216-224. doi: 10.3760/cma.j.cn501225-20250606-00257.
[11]	Gong HP, Ren Y, Swe TH, et al. Age-related variations in clinical characteristics of patients with diabetic foot ulcers[J]. J Diabetes Investig, 2026, 17(1):96-102.doi: 10.1111/jdi.70181.
[12]	Lin C, Tian J, Zhang Z, et al. Risk factors associated with the recurrence of diabetic foot ulcers: A meta-analysis[J]. PLoS One, 2025, 20(2):e0318216.doi: 10.1371/journal.pone.0318216.
[13]	Yao Y, Chen L, Qian Y. Age characteristics of patients with type 2 diabetic foot ulcers and predictive risk factors for lower limb amputation: A population-based retrospective study[J]. J Diabetes Res, 2024, 2024:2380337.doi: 10.1155/jdr/2380337.
[14]	Zhang S, Chen J, Sun R, et al. Analysis of the species distribution and drug resistance of pathogenic microorganisms causing diabetic foot infections in Southwest China from 2020 to 2024: A retrospective cross-sectional analysis[J]. Naunyn Schmiedebergs Arch Pharmacol, 2026.doi: 10.1007/s00210-026-05167-2.Epubaheadofprint.
[15]	Su G, Yuan X, Yuan G, et al. Exploration of predictive risk factors for diabetic foot in patients with diabetes in Beijing: analysis of 5-year follow-up data of patients with diabetes mellitus in a single center in Beijing[J]. Front Endocrinol (Lausanne), 2024, 15:1441997. doi: 10.3389/fendo.2024.1441997.
[16]	Zhou Z, Jia Y, Yan H, et al. Risk prediction models for patients with recurrent diabetic foot ulcers: A systematic review[J]. Public Health, 2025, 244:105744.doi: 10.1016/j.puhe.2025.
[17]	Luo Y, Liu C, Li C, et al. The incidence of lower extremity amputation and its associated risk factors in patients with diabetic foot ulcers: A meta-analysis[J]. Int Wound J, 2024, 21(7):e14931.doi: 10.1111/iwj.14931.
[18]	Che D, Jiang Z, Xiang X, et al. Predictors of amputation in patients with diabetic foot ulcers: A multi-centre retrospective cohort study[J]. Endocrine, 2024, 85(1):181-189.doi: 10.1007/s12020-024-03704-8. pmid: 38332209
[19]	Chen L, Chen D, Gong H, et al. Pedal medial arterial calcification in diabetic foot ulcers: A significant risk factor of amputation and mortality[J]. J Diabetes, 2024, 16(4):e13527.doi: 10.1111/1753-0407.13527.
[20]	Wu D, Yu Y, Zheng H, et al. Analysis of the risk of death and its associated risk factors in Chinese patients with young-onset type 2 diabetes[J]. Front Endocrinol (Lausanne), 2024, 15:1451364.doi: 10.3389/fendo.2024.1451364.
[21]	Ye W, Li L, Zeng J. Association of cardiac valve calcification and 1-year mortality after lower-extremity amputation in diabetic patients: A retrospective study[J]. Curr Neurovasc Res, 2024, 20(5):599-607.doi: 10.2174/0115672026277348231130112221.
[22]	Liao YD, Chen Y, Ma XK, et al. [ Clinical effect of tibial transverse transport technique combined with continuous low negative pressure wound therapy in the treatment of Wagner grade Ⅲ to Ⅴ chronic diabetic foot ulcers][J]. Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi, 2025, 41(10):968-976. doi: 10.3760/cma.j.cn501225-20241106-00436.
[23]	Qu YD, Ou SJ, Zhang W, et al. Microbiological profile of diabetic foot infections in China and worldwide: A 20-year systematic review[J]. Front Endocrinol (Lausanne), 2024, 15:1368046.doi: 10.3389/fendo.2024.1368046.
[24]	Zhang X, Liu G, You Y, et al. Bone marrow-derived mesenchymal stem cells combined with intramuscular injection promote the healing of diabetic foot ulcers: A systematic review and meta-analysis[J]. Front Endocrinol (Lausanne), 2026, 17:1763071.doi: 10.3389/fendo.2026.1763071.
[25]	Zhang H, Gu Y, Zhang K, et al. Safety and efficacy of umbilical cord mesenchymal stem cell therapy for diabetic foot ulcers and peripheral artery disease: A systematic review and meta-analysis of randomized controlled trials[J]. Int J Low Extrem Wounds,2026:15347346261426552.doi: 10.1177/15347346261426552.
[26]	Tong L, Tang L, Tang B, et al. Impacts of stem cells from different sources on wound healing rate in diabetic foot ulcers: A systematic review and meta-analysis[J]. Front Genet, 2024, 15:1541992. doi: 10.3389/fgene.2024.1541992.
[27]	Li X, Liang Z. Efficacy and safety of antibiotic-loaded bone cement in the treatment of diabetic foot: A systematic review and meta-analysis[J]. Front Cell Infect Microbiol, 2026, 16:1748750. doi: 10.3389/fcimb.2026.1748750.
[28]	Zhang J, Zhao Y, Hu Z, et al. Efficacy and safety of biomaterials and antimicrobial dressings in the treatment of diabetic foot ulcers: A systematic review and network meta-analysis[J]. J Diabetes Res, 2025, 2025:1548984.doi: 10.1155/jdr/1548984.
[29]	Liang H, Deng P, Yang L, et al. Sequential treatment for diabetic foot ulcers in aortic dissection patients: A case report[J]. Front Endocrinol (Lausanne), 2025, 16:1635004.doi: 10.3389/fendo.2025.1635004.
[30]	Su Y, Fu X, Huang Y. Consensus statement on the clinical application of extracorporeal shock wave therapy for diabetic foot ulcers (2025 Edition)[J]. Int J Surg, 2026, 112(1):71-83.doi: 10.1097/JS9.0000000000003489.
[31]	Lan X, Huang Z, Zheng Y, et al. Electrical stimulation as an adjunctive therapy for diabetic ulcers: A systematic review and meta-analysis[J]. Int Wound J, 2024, 21(12):e70104.doi: 10.1111/iwj.70104.
[32]	Chinese Burn Association, the Yangtze River Delta Integrated Diabetic Foot Alliance, and the Editorial Committee of the Chinese Journal of Burns and Wound Repair, et al. Practical guidelines for the prevention and management of diabetic foot disease in China[J]. Burns Trauma, 2025,13:tkaf064.doi: 10.1093/burnst/tkaf064.
[33]	Yong E, Gong H, Liew H, et al. Getting a foothold on diabetic foot disease-outcomes of a multidisciplinary clinical pathway for inpatient diabetic foot care: A 17-year institutional review[J]. Int J Low Extrem Wounds, 2025, 24(1):177-185.doi: 10.1177/15347346231183740.
[34]	Liu Y, Riklikiene O, Ezenwaka C, et al. Key challenges in nurse-led foot care education for persons with diabetes: An international survey across six countries[J]. BMC Nurs, 2026, 25(1):204. doi: 10.1186/s12912-026-04457-7.
[35]	Zhu W, Zhang L, Long S, et al. Navigating challenges in the delivery of diabetic foot self-care education: Perspectives of nurses in rural southwest China[J]. Adv Skin Wound Care, 2025, 38(6):316-322.doi: 10.1097/ASW.0000000000000290. pmid: 40168624
[36]	Xie Y, Liu Z, Ming Y, et al. The effect of a nurse-led health education intervention on treatment delay in patients with diabetic high-risk foot: A randomised controlled trial[J]. Int J Nurs Stud, 2026, 175:105316.doi: 10.1016/j.ijnurstu.2025.105316.
[37]	Zhou J, Ding S, Xu Y, et al. Effects of digital intelligent interventions on self-management of patients with diabetic foot: Systematic review[J]. J Med Internet Res, 2025, 27:e64400.doi: 10.2196/64400.

核心举措	具体内容与实施细节
国家糖尿病中心协会(NADC)认证标准	涵盖人员配备、设备配置、服务流程、患者结局等8项核心标准;采用分级认证体系,分为“核心标准认证”与“卓越中心认证”两级,形成递进式质量要求;截至2024年,已有19家中心获核心认证,17家被评为卓越中心
多学科团队(MDT)制度化配置	团队成员法定包括足病医生、糖尿病医生、骨科医生、血管外科医生、微生物学家、放射科医生、矫形器专家、理疗师;明确要求各专业紧密协作而非单一科室独立运作;在缺乏足病医生时可由其他经培训的团队成员替代
澳大利亚糖尿病足登记处(ADFR)	借助REDCap工具实现全国标准化数据收集与多中心基准对比;审计数据显示数据完整性高达99%;审计结果用于识别临床实践中的薄弱环节,如周围动脉疾病(PAD)评估率不足和溃疡复发预防待加强
2021年循证指南及2023年IWGDF更新	2021年发布《糖尿病相关足病循证指南》,系统性涵盖预防策略、风险分层、溃疡分类、感染管理、血运重建等多模块;2023年国际糖尿病足工作组(IWGDF)更新全球指南,进一步强化多学科协作和个性化治疗推荐
FootForward教育与工具包	为医护人员提供包含临床路径、实用技巧、海报和视频在内的教育资源包;培训重点覆盖SINBAD伤口分类系统、标准化减压技术、感染识别与管理等关键技能
量化健康目标与预后研究	《2030糖尿病足健康策略》设定清晰目标,即5年内将全国截肢率降低50%;研究发现大多数溃疡可通过保守治疗实现愈合,早期转诊至MDT可显著改善预后
D-Foot西太平洋地区合作网络	推动区域内各国在足病诊疗标准、数据共享、指南适配方面的协同;中国学者参与其中,致力于国际指南的本土化应用和多中心研究合作

核心举措	具体内容与实施细节
国家糖尿病中心协会(NADC)认证标准	涵盖人员配备、设备配置、服务流程、患者结局等8项核心标准;采用分级认证体系,分为“核心标准认证”与“卓越中心认证”两级,形成递进式质量要求;截至2024年,已有19家中心获核心认证,17家被评为卓越中心
多学科团队(MDT)制度化配置	团队成员法定包括足病医生、糖尿病医生、骨科医生、血管外科医生、微生物学家、放射科医生、矫形器专家、理疗师;明确要求各专业紧密协作而非单一科室独立运作;在缺乏足病医生时可由其他经培训的团队成员替代
澳大利亚糖尿病足登记处(ADFR)	借助REDCap工具实现全国标准化数据收集与多中心基准对比;审计数据显示数据完整性高达99%;审计结果用于识别临床实践中的薄弱环节,如周围动脉疾病(PAD)评估率不足和溃疡复发预防待加强
2021年循证指南及2023年IWGDF更新	2021年发布《糖尿病相关足病循证指南》,系统性涵盖预防策略、风险分层、溃疡分类、感染管理、血运重建等多模块;2023年国际糖尿病足工作组(IWGDF)更新全球指南,进一步强化多学科协作和个性化治疗推荐
FootForward教育与工具包	为医护人员提供包含临床路径、实用技巧、海报和视频在内的教育资源包;培训重点覆盖SINBAD伤口分类系统、标准化减压技术、感染识别与管理等关键技能
量化健康目标与预后研究	《2030糖尿病足健康策略》设定清晰目标,即5年内将全国截肢率降低50%;研究发现大多数溃疡可通过保守治疗实现愈合,早期转诊至MDT可显著改善预后
D-Foot西太平洋地区合作网络	推动区域内各国在足病诊疗标准、数据共享、指南适配方面的协同;中国学者参与其中,致力于国际指南的本土化应用和多中心研究合作

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 1

References 37

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhou Dian;Wang Wen;Yu Junji;Lv Guozhong. Distribution and drug resistance of pathogenic bacteria in diabetic foot infection [J]. Clinical Focus, 2015, 30(3): 304-307.
[2]	LI Xi-wen;WANG Peng-hua;CHU Yue-jie;JIAO Jiao;JI Xiao-yan. Impact of peer education on diabetic foot patients with depression on basis of psychological intervention [J]. Clinical Focus, 2014, 29(6): 679-682.
[3]	. [J]. Clinical Focus, 2014, 29(6): 695-696.
[4]	JI Xiao-yan;WANG Peng-hua;CHU Yue-jie;JIAO Jiao;LI Xi-wen. Clinical characteristics and related factors of diabetic foot ulcer with multi-drug resistant microorganisms infection [J]. CLINICAL FOCUS, 2014, 29(2): 134-137.
[5]	. [J]. CLINICAL FOCUS, 2013, 28(8): 908-909.
[6]	ZHOU Lu;ZHOU Wei-hui. Clinical observation on treatment of diabitic peripheral neuropathy in 70 patients with Pushen capsule [J]. Clinical Focus, 2013, 28(4): 400-402.
[7]	. [J]. Clinical Focus, 2013, 28(2): 210-211.
[8]	. [J]. CLINICAL FOCUS, 2011, 26(14): 1275-1277.
[9]	WANG Lin;SUN Wei. Clinical value of color Doppler ultrasound for lower extremity artery in diabetes patients [J]. CLINICAL FOCUS, 2011, 26(8): 669-672.
[10]	. [J]. CLINICAL FOCUS, 2010, 25(23): 2099-0.
[11]	. [J]. CLINICAL FOCUS, 2010, 25(11): 967-969.
[12]	. [J]. CLINICAL FOCUS, 2010, 25(11): 1008-1010.
[13]	XU Jin-xiu;LI Xin-sheng;LI Jia-rui;ZHANG Jin-cheng;WANG Guang-ya;LI Yu-kun. Relation between blood fibrinogen and lower extremity vasculopathy in type 2 diabetic patients [J]. CLINICAL FOCUS, 2010, 25(6): 492-494.
[14]	. [J]. CLINICAL FOCUS, 2009, 24(16): 1432-1433.
[15]	. [J]. CLINICAL FOCUS, 2009, 24(6): 551-0.